Dr. Shannon Trotter explains to her melanoma patients how the DecisionDx-Melanoma test provides personalized insights by analyzing the specific gene expression of a patient’s melanoma. Using an analogy, she describes how the test helps predict whether a melanoma will behave "cooperatively" according to standard staging or show signs of a more aggressive profile. By examining upregulated and downregulated genes within the tumor, DecisionDx-Melanoma offers valuable information that allows clinicians to tailor treatment and follow-up strategies based on each patient’s unique tumor biology. Discover how this advanced test is changing melanoma care with individualized predictions and treatment planning.
